Mesoblast Limited

What they do

Mesoblast is a biological products company organized as one reportable segment. It develops and commercializes allogeneic cellular medicines, with RYONCIL (remestemcel-L) as its approved product for steroid-refractory acute graft versus host disease in pediatric patients. The company also recognizes revenue from government rebates, distributor fees, and co-pay assistance programs that adjust gross sales. Its 20-F for fiscal year 2026 shows the company remains reliant on debt facilities and equity capital to fund operations.

Revenue drivers

• RYONCIL (remestemcel-L) — The company's only named marketed product, generating U.S. sales subject to gross-to-net deductions including government rebates and chargebacks, distributor fees, other sales deductions, and co-pay assistance.
• Gross-to-net adjustments — Revenue is reduced by government rebates/chargebacks, discounts and distributor fees, other sales-related deductions, and co-pay assistance; these deductions are tracked across fiscal 2024, 2025 and 2026 in the 20-F.
• Debt financing facilities — The company has credit line facilities as well as senior debt facilities with Oaktree Capital Management and a loan and security agreement with NovaQuest Capital Management, which finance operations and are tied to warrants and American Depositary Shares.
• Equity and warrant activity — The 20-F shows movements in issued capital, convertible instrument reserves, and warrant accounting associated with the credit line facility, indicating equity-linked financing supports the business.

Recent performance

The 20-F for fiscal year 2026, filed 2026-08-27, presents results for fiscal years 2026, 2025 and 2024. Revenue is reported net of significant gross-to-net deductions, with separate adjustments shown for government rebates and chargebacks, discounts and distributor fees, other sales-related deductions, and co-pay assistance. Operating expenses are presented by function, with research and development and selling, general and administrative expense categories disclosed across the three years. The company reports unused tax losses for fiscal 2026, 2025 and 2024, and holds financial assets at amortised cost as well as financial liabilities at amortised cost and at fair value through profit or loss. Specific revenue, net income, and cash figures are not included in the provided excerpts.

Strategy

Mesoblast's disclosed financing strategy includes a credit line facility and senior debt facilities with Oaktree Capital Management and NovaQuest Capital Management. The company has issued warrants and engaged in American Depositary Share activity associated with its credit line facility. Its cost structure is managed across research and development and selling, general and administrative functions, reflecting continued investment in its cell therapy business. The 20-F also discloses unused tax losses, which may be available to offset future taxable income subject to applicable rules. No specific product pipeline expansion or partnership strategy beyond the named financings is described in the provided excerpts.

Risks

• Concentration in a single product — Revenue is tied to RYONCIL (remestemcel-L), so any decline in demand, reimbursement, or manufacturing for that product would materially affect the company.
• Gross-to-net deduction pressure — Government rebates, chargebacks, distributor fees, and co-pay assistance reduce reported net revenue from RYONCIL sales.
• Debt and warrant dilution — The company relies on credit line and senior debt facilities from Oaktree and NovaQuest, with associated warrants and American Depositary Shares that can dilute existing holders.
• Accumulated tax losses and profitability risk — The 20-F discloses unused tax losses across fiscal 2026, 2025 and 2024, indicating a history of losses and uncertain timing of future taxable profits.

Outlook

The provided excerpts do not include management's specific forward-looking guidance. The filing discloses ongoing credit facilities, warrants, and unused tax losses, suggesting continued reliance on external financing. No revenue or earnings targets are stated in the excerpts.